Experience with the use of netakimab for the treatment of psoriasis in HIV-infected patients

DOI: https://dx.doi.org/10.18565/pharmateca.2022.8.91-96

E.Yu. Evdokimov, Zh.B. Ponezheva, E.V. Svechnikova, B.M. Gruzdev

1) Central Research Institute of Epidemiology, Moscow, Russia; 2) Polyclinic № 1 of the Department for Presidential Affairs of the Russian Federation, Moscow, Russia; 3) Novosibirsk State Medical University, Novosibirsk, Russia; 4) Infectious Clinical Hospital № 2 of the Moscow Healthcare Department, Moscow, Russia
Background. In HIV-infected patients, psoriasis is classified as a common skin pathology; it often occurs in severe forms in this category of patients. In this regard, the issues of psoriasis therapy, the use of modern methods of treatment remain relevant.
Objective. Evaluation of the possibility of using the drug Netakimab in HIV-infected patients.
Methods. Five HIV-infected patients with psoriasis vulgaris were followed-up; all patients received antiretroviral therapy (ART). There were 4 men (80%), 1 woman (20%). The mean age in the groups was 36.4 years (from 32 to 41 years). The mean duration of psoriasis was 7.6 years (from 0.5 to 17 years); in one patient, psoriasis developed against the background of HIV infection (3 months after the verification of the HIV diagnosis). PASI was 17.5 (from 14.8 to 35.4). 3 patients had psoriatic arthropathy. The mean duration of HIV infection was 4.5 years (range 0.5 to 9 years), duration of ART was on average 2.5 years (range 0.5 to 7.2 years). All patients underwent the necessary examination before using Netakimab.
Results. after 14 weeks of therapy, there was a significant improvement in skin status, a decrease in the inflammatory process in the joints with a complete resolution of the pain syndrome in HIV-infected patients with psoriasis. There was no deterioration in the indicators of HIV infection (clinical course, a decrease in the number of CD4+ lymphocytes, an increase in the HIV viral load).
Conclusion. Netakimab in HIV-infected patients can be used to treat severe forms of psoriasis.

About the Autors

Corresponding author: Evgeny Yu. Evdokimov, Cand. Sci. (Med.), Researcher at the Clinical Department, Central Research Institute of Epidemiology, Moscow, Russia; evdokimovevg@yandex.ru

Similar Articles

Бионика Медиа